(NASDAQ: ALNY) Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. Investors to Contact the Firm

Impact · against what's priced in

Alnylam faces a negative outlook as the market digests a $200 million revenue cut for its TTR product and the subsequent initiation of a securities fraud investigation. Primoris Services is facing a deadline in a securities fraud class action, adding legal uncertainty to its profile.

ALNY−0.70

No priced-in read yet